Understanding Barriers Towards Availability of Childhood Cancer Drugs in Cancer Treatment Centers Pharmacies in Tanzania.
Material type:
TextPublisher number: Wurzburg Road 35, BMC Premises, Post Code: 33102: P. O Box 1464, Mwanza – Tanzania: Phone: +255 28 298 3384: Fax: +255 28 298 3386: Email: vc@bugando.ac.tz :www.bugando.ac.tzLanguage: English Publication details: Mwanza, Tanzania: Catholic University of Health and Allied Sciences [CUHAS - Bugando] : 2020Description: xiv; 147 Pages; Includes References and AppendicesSubject(s): Summary: Abstract:
Background: Cancer is a growing burden in most low and middle income countries and affects all age groups. It is estimated over 300,000 children develop cancer annually in the world with 8 out of 10 of children residing in low and middle income countries. Availability of essential childhood cancer drugs is crucial for provision of quality care. Barriers towards childhood cancer drug availability such as delivery delays, under delivery and frequent stock outs hinders drug availability in facilities providing cancer care. This study aims to understand barriers to childhood cancer drugs availability in Tanzania with special attention to policies that enhance drug availability.
Methods: This study employed a qualitative case study and qualitative crossectional study design, purposive and snowballing sampling procedure was employed to obtain stakeholders involved in childhood cancer drug procurement and provision in Tanzania. A key informant interview guide that included a checklist of 17 anticancer drugs used to treat 4common childhood cancer, as well as document reviews were used to provide an insight of barriers and regulations towards childhood cancer drugs availability in Tanzania. Data analysis was done following thematic analysis steps while availability of drugs was analysed using percentages and data from document reviews was described. Ethical clearance was sought from Catholic University Health and Allied Sciences and Bugando Medical Center research and ethics review committee and National Health Research Ethics Committee.
Results: Childhood cancer drugs availability survey revealed 74.4% and 88.2% availability in Bugando and Muhimbili hospitals while 94.1% and 88.2% in Okinawa and Casmedics respectively. Five themes emerged as barriers towards childhood drug availability which were; complex processes of childhood cancer drugs registration, high childhood cancer drugs costs, price fluctuations experienced by suppliers of childhood cancer drugs in Tanzania, preference of suppliers of childhood cancer drugs and unreliable supply of childhood cancer drugs in the country.
Conclusion: Understanding insight of stakeholders on barriers leading to unavailability of these drugs in the country highlights potential areas that could be worked on to improve availability of childhood cancer drugs.
| Item type | Current library | Collection | Status | Barcode | |
|---|---|---|---|---|---|
| POSTGRADUATE DISSERTATIONS | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | NFIC | 1 | PD0378 |
Abstract:
Background: Cancer is a growing burden in most low and middle income countries and affects all age groups. It is estimated over 300,000 children develop cancer annually in the world with 8 out of 10 of children residing in low and middle income countries. Availability of essential childhood cancer drugs is crucial for provision of quality care. Barriers towards childhood cancer drug availability such as delivery delays, under delivery and frequent stock outs hinders drug availability in facilities providing cancer care. This study aims to understand barriers to childhood cancer drugs availability in Tanzania with special attention to policies that enhance drug availability.
Methods: This study employed a qualitative case study and qualitative crossectional study design, purposive and snowballing sampling procedure was employed to obtain stakeholders involved in childhood cancer drug procurement and provision in Tanzania. A key informant interview guide that included a checklist of 17 anticancer drugs used to treat 4common childhood cancer, as well as document reviews were used to provide an insight of barriers and regulations towards childhood cancer drugs availability in Tanzania. Data analysis was done following thematic analysis steps while availability of drugs was analysed using percentages and data from document reviews was described. Ethical clearance was sought from Catholic University Health and Allied Sciences and Bugando Medical Center research and ethics review committee and National Health Research Ethics Committee.
Results: Childhood cancer drugs availability survey revealed 74.4% and 88.2% availability in Bugando and Muhimbili hospitals while 94.1% and 88.2% in Okinawa and Casmedics respectively. Five themes emerged as barriers towards childhood drug availability which were; complex processes of childhood cancer drugs registration, high childhood cancer drugs costs, price fluctuations experienced by suppliers of childhood cancer drugs in Tanzania, preference of suppliers of childhood cancer drugs and unreliable supply of childhood cancer drugs in the country.
Conclusion: Understanding insight of stakeholders on barriers leading to unavailability of these drugs in the country highlights potential areas that could be worked on to improve availability of childhood cancer drugs.
There are no comments on this title.
Click on an image to view it in the image viewer